Literature DB >> 11129464

Identifying combinations of cancer markers for further study as triggers of early intervention.

S G Baker1.   

Abstract

In many long-term clinical trials or cohort studies, investigators repeatedly collect and store tissue or serum specimens and later test specimens from cancer cases and a random sample of controls for potential markers for cancer. An important question is what combination, if any, of the molecular markers should be studied in a future trial as a trigger for early intervention. To answer this question, we summarized the performance of various combinations using Receiver Operating Characteristic (ROC) curves, which plot true versus false positive rates. To construct the ROC curves, we proposed a new class of nonparametric algorithms which extends the ROC paradigm to multiple tests. We fit various combinations of markers to a training sample and evaluated the performance in a test sample using a target region based on a utility function. We applied the methodology to the following markers for prostate cancer, the last value of total prostate-specific antigen (PSA), the last ratio of total to free PSA, the last slope of total PSA, and the last slope of the ratio. In the test sample, the ROC curve for last total PSA was slightly closer to the target region than the ROC curve for a combination of four markers. In a separate validation sample, the ROC curve for last total PSA intersected the target region in 77% of bootstrap replications, indicating some promise for further study. We also discussed sample size calculations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11129464     DOI: 10.1111/j.0006-341x.2000.01082.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  24 in total

1.  Homogeneity tests of clustered diagnostic markers with applications to the BioCycle Study.

Authors:  Liansheng Larry Tang; Aiyi Liu; Enrique F Schisterman; Xiao-Hua Zhou; Catherine Chun-Ling Liu
Journal:  Stat Med       Date:  2012-06-26       Impact factor: 2.373

2.  RE: Leveraging Biospecimen Resources for Discovery or Validation of Markers for Early Cancer Detection.

Authors:  Stuart G Baker
Journal:  J Natl Cancer Inst       Date:  2015-09       Impact factor: 13.506

3.  Using the optimal receiver operating characteristic curve to design a predictive genetic test, exemplified with type 2 diabetes.

Authors:  Qing Lu; Robert C Elston
Journal:  Am J Hum Genet       Date:  2008-03       Impact factor: 11.025

4.  Assessing the incremental value of new biomarkers based on OR rules.

Authors:  Lu Wang; Alexander R Luedtke; Ying Huang
Journal:  Biostatistics       Date:  2020-07-01       Impact factor: 5.899

5.  ROC analysis for multiple markers with tree-based classification.

Authors:  Mei-Cheng Wang; Shanshan Li
Journal:  Lifetime Data Anal       Date:  2012-10-10       Impact factor: 1.588

6.  Improving the biomarker pipeline to develop and evaluate cancer screening tests.

Authors:  Stuart G Baker
Journal:  J Natl Cancer Inst       Date:  2009-07-02       Impact factor: 13.506

7.  Bivariate marker measurements and ROC analysis.

Authors:  Mei-Cheng Wang; Shanshan Li
Journal:  Biometrics       Date:  2012-09-24       Impact factor: 2.571

8.  Prediction of uterine rupture associated with attempted vaginal birth after cesarean delivery.

Authors:  William A Grobman; Yinglei Lai; Mark B Landon; Catherine Y Spong; Kenneth J Leveno; Dwight J Rouse; Michael W Varner; Atef H Moawad; Steve N Caritis; Margaret Harper; Ronald J Wapner; Yoram Sorokin; Menachem Miodovnik; Marshall Carpenter; Mary J O'Sullivan; Baha M Sibai; Oded Langer; John M Thorp; Susan M Ramin; Brian M Mercer
Journal:  Am J Obstet Gynecol       Date:  2008-04-25       Impact factor: 8.661

9.  Using the optimal robust receiver operating characteristic (ROC) curve for predictive genetic tests.

Authors:  Qing Lu; Nancy Obuchowski; Sungho Won; Xiaofeng Zhu; Robert C Elston
Journal:  Biometrics       Date:  2009-06-08       Impact factor: 2.571

10.  Learning-based biomarker-assisted rules for optimized clinical benefit under a risk constraint.

Authors:  Yanqing Wang; Ying-Qi Zhao; Yingye Zheng
Journal:  Biometrics       Date:  2019-12-25       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.